Q2 revenue of $6.0 million, including license revenue
Nearly 1,000 prospective MyoPro® candidates with known payers in the patient pipeline
Begins to build Medicare Part B patient pipeline following publication of proposed rule by the Centers for Medicare and Medicaid Services
Conference call begins at 4:30 p.m. Eastern time today
BOSTON (August 9, 2023) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2023. Read more.